The adult bovine serum market is anticipated to expand due to rising demand for biopharmaceuticals and vaccines. Biotechnology is used to create biopharmaceuticals, which are pharmaceuticals that come from biological sources like humans, animals, and microorganisms. They are created utilising tissue culture techniques, stem cells, mammalian cells, etc. The production of therapeutic recombinant molecules or biopharmaceuticals requires the employment of cell culture technologies, which have a variety of vital components that preserve the integrity of the cell culture and supply nutrients and signals. Adult bovine serum (ABS) is one of these cell culture components. To promote the development and proliferation of several cell types, ABS is frequently added to basal cell culture media. A rise in demand for adult bovine serum in culture medium has been attributed to rising demand for biopharmaceuticals and vaccinations throughout time. The global adult bovine serum market is anticipated to increase as a result of the growing availability of adult bovine serum from various sources. Key market participants' increased sourcing of adult bovine serum from New Zealand is anticipated to support market expansion over the forecast period.
Coherent Market Insights projects that the market for Adult Bovine Serum is anticipated to be worth US$ 119.3 million in 2022 and US$ 185.1 million by 2030, growing at a 5.6% CAGR during the forecast period (2022-2030).
Top Companies in the Adult Bovine Serum Industry:
1. Sartorius AG
The firm was established in 1870 and has its headquarters in Göttingen, Germany. Sartorius AG produces and sells components and machinery for precise electronic systems. The business manufactures precision scales for electrochemistry, industrial, and laboratory applications. Sartorius produces machinery for cell culture, concentration, fermentation, and purification as well as biomolecular and microbial separations. In 2020, the business purchased a number of Danaher Corporation's assets, including items for the study and creation of cell treatments.
2. Thermo Fisher Scientific
The company was started in 1956 and is located in Waltham, Massachusetts, U.S. The business offers applications, reagents and consumables, and scientific apparatus. Thermo Fisher Scientific stated in January 2021 that it had purchased Groupe Novasep SAS's viral vector maker, Henogen SA, in Belgium. In an all-cash agreement worth US$2.6 billion, the business agreed to acquire Nordic Capital's British diagnostics company, The Binding Site Group, in October 2022.